figshare
Browse
12885_2021_8965_MOESM2_ESM.docx (38.06 kB)

Additional file 2 of The WIRE study a phase II, multi-arm, multi-centre, non-randomised window-of-opportunity clinical trial platform using a Bayesian adaptive design for proof-of-mechanism of novel treatment strategies in operable renal cell cancer – a study protocol

Download (38.06 kB)
journal contribution
posted on 2021-11-19, 04:34 authored by Stephan Ursprung, Helen Mossop, Ferdia A. Gallagher, Evis Sala, Richard Skells, Jamal A. N. Sipple, Thomas J. Mitchell, Anita Chhabra, Kate Fife, Athena Matakidou, Gemma Young, Amanda Walker, Martin G. Thomas, Mireia Crispin Ortuzar, Mark Sullivan, Andrew Protheroe, Grenville Oades, Balaji Venugopal, Anne Y. Warren, John Stone, Tim Eisen, James Wason, Sarah J. Welsh, Grant D. Stewart
Additional file 2.

Funding

Cancer Research UK Cambridge Centre NIHR Cambridge Biomedical Research Centre AstraZeneca (GB)

History

Usage metrics

    BMC Cancer

    Categories

    Keywords

    Clinical trial protocol [MeSH]Clear cell renal cell carcinoma [MeSH]Phase II clinical trial [MeSH]Bayesian adaptive trialOlaparib [MeSH]Cediranib [MeSH]Durvalumab [MeSH]Window-of-opportunityNeoadjuvant therapy [MeSH]

    Licence

    CC BY + CC0

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC